{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:40:00Z","timestamp":1788921600385,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40262-021-01083-1","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T01:02:23Z","timestamp":1637110943000},"page":"451-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Finerenone Dose\u2013Exposure\u2013Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria"],"prefix":"10.1007","volume":"61","author":[{"given":"Sebastiaan Camiel","family":"Goulooze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Snelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Seelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Horvat-Broecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Garmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-3423","authenticated-orcid":false,"given":"Thomas","family":"Eissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"issue":"23","key":"1083_CR1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"5","key":"1083_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333\u201344.","journal-title":"Am J Nephrol"},{"key":"1083_CR3","doi-asserted-by":"crossref","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021.","DOI":"10.1056\/NEJMoa2110956"},{"issue":"3","key":"1083_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ddr.21760","volume":"82","author":"V Patel","year":"2021","unstructured":"Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev Res. 2021;82(3):341\u201363.","journal-title":"Drug Dev Res"},{"issue":"1","key":"1083_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40620-019-00600-7","volume":"33","author":"I Capelli","year":"2020","unstructured":"Capelli I, Gasperoni L, Ruggeri M, Donati G, Baraldi O, Sorrenti G, et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol. 2020;33(1):37\u201348.","journal-title":"J Nephrol"},{"issue":"3","key":"1083_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, et al. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370.","journal-title":"Clin Pharmacokinet"},{"key":"1083_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01082-2","author":"P van den Berg","year":"2021","unstructured":"van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, et al. Finerenone dose-exposure-primary efficacy response in FIDELIO-DKD phase 3\u2014population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet. 2021. https:\/\/doi.org\/10.1007\/s40262-021-01082-2.","journal-title":"Clin Pharmacokinet"},{"key":"1083_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143:540\u201352.","journal-title":"Circulation"},{"issue":"2","key":"1083_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cpt.2162","volume":"110","author":"TW Schnider","year":"2021","unstructured":"Schnider TW, Minto CF, Filipovic M. The drug titration paradox: correlation of more drug with less effect in clinical data. Clin Pharmacol Ther. 2021;110(2):401\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"9 Suppl","key":"1083_CR10","doi-asserted-by":"publisher","first-page":"91S","DOI":"10.1177\/0091270010376965","volume":"50","author":"DR Mould","year":"2010","unstructured":"Mould DR, Frame B. Population pharmacokinetic\u2013pharmacodynamic modeling of biological agents: when modeling meets reality. J Clin Pharmacol. 2010;50(9 Suppl):91S-100S.","journal-title":"J Clin Pharmacol"},{"key":"1083_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-244X-8-3","volume":"8","author":"I Lipkovich","year":"2008","unstructured":"Lipkovich I, Adams DH, Mallinckrodt C, Faries D, Baron D, Houston JP. Evaluating dose response from flexible dose clinical trials. BMC Psychiatry. 2008;8:3.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1083_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/pst.1498","volume":"11","author":"XS Xu","year":"2012","unstructured":"Xu XS, Yuan M, Nandy P. Analysis of dose-response in flexible dose titration clinical studies. Pharm Stat. 2012;11(4):280\u20136.","journal-title":"Pharm Stat"},{"issue":"3","key":"1083_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.conb.2007.04.004","volume":"17","author":"G Turrigiano","year":"2007","unstructured":"Turrigiano G. Homeostatic signaling: the positive side of negative feedback. Curr Opin Neurobiol. 2007;17(3):318\u201324.","journal-title":"Curr Opin Neurobiol"},{"issue":"127","key":"1083_CR14","doi-asserted-by":"publisher","first-page":"20160848","DOI":"10.1098\/rsif.2016.0848","volume":"14","author":"HM Sauro","year":"2017","unstructured":"Sauro HM. Control and regulation of pathways via negative feedback. J R Soc. 2017;14(127):20160848.","journal-title":"J R Soc"},{"issue":"6","key":"1083_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cell.2004.09.008","volume":"118","author":"J Stelling","year":"2004","unstructured":"Stelling J, Sauer U, Szallasi Z, Doyle FJ 3rd, Doyle J. Robustness of cellular functions. Cell. 2004;118(6):675\u201385.","journal-title":"Cell"},{"issue":"17","key":"1083_CR16","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","volume":"39","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39(17):1535\u201342.","journal-title":"Eur Heart J"},{"issue":"7","key":"1083_CR17","doi-asserted-by":"publisher","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","volume":"6","author":"G Bandak","year":"2017","unstructured":"Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6(7):e005428.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"1083_CR18","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2337\/dc08-2151","volume":"32","author":"T Babazono","year":"2009","unstructured":"Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, Suzuki K, et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care. 2009;32(8):1518\u201320.","journal-title":"Diabetes Care"},{"issue":"9","key":"1083_CR19","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","volume":"20","author":"G Savarese","year":"2018","unstructured":"Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20(9):1326\u201334.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1083_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127.","journal-title":"BMC Nephrol"},{"key":"1083_CR21","unstructured":"FDA. US Prescribing Information. 2021. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215341s000lbl.pdf. Accessed 16 July 2021."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01083-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:05:17Z","timestamp":1646283917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01083-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01083-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"8 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P) conducted the analysis as contract research for Bayer. However, LAP&P (SCG, NS) were not paid to contribute to the manuscript preparation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SCG and NS are employed by LAP&P, a contract research organization working for Bayer. AS, AHB, MB, AJ, DG, JL, and TE are Bayer employees and potential shareholders of Bayer AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data will be made available in an electronic repository in future, at a date to be specified by Bayer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"NONMEM analysis code is provided in the ESM.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study protocol was approved by international review boards, independent ethics committees, and competent authorities according to national and international regulations. FIDELIO-DKD was conducted in accordance with the ICH Harmonized Tripartite Guideline for Good Clinical Practice.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided written informed consent before entering the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All study participants provided written informed consent before entering the study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}